Samsung Biologics Showcases Agile and Flexible CDO Competitiveness

20% Shorter Development Timeline Than Industry Standard
"Supporting Clients With Tailored Strategies"

Samsung Biologics announced on the 16th that it actively promoted its outstanding competitiveness in CDO (Contract Development Organization) services at 'BioPlus-Interphex Korea 2025 (BIX 2025)', the largest comprehensive pharmaceutical and biotech expo in Korea.

Lee Taehee, Executive Director and Head of the Antibody Cultivation PD Team at Samsung Biologics, is presenting on the competitiveness of CDO services at the BIX 2025 luncheon session held on Tuesday, the 16th. Samsung Biologics

At the BIX 2025 conference, Samsung Biologics hosted a luncheon session titled 'Streamlining Drug Development: From Developability Assessment to IND Submission', showcasing its CDO service capabilities aimed at shortening the development timelines for clients' new drug candidates. The session, which was limited to 100 pre-registered participants, quickly reached capacity, reflecting the industry's strong interest in Samsung Biologics' CDO technology.

Lee Taehee, Executive Director and Head of the Antibody Cultivation PD Team, who led the presentation, explained, "By conducting early-stage developability assessments, establishing risk-based CMC (Chemistry, Manufacturing, and Controls) plans, and introducing parallel workflows, we have reduced the complexity of the development process and increased speed without compromising quality. As a result, we have shortened the timeline from antibody drug candidate selection to IND (Investigational New Drug) submission to about eight months, compared to the industry standard of ten months."

Lee Taehee further emphasized, "We are actively responding to the diverse needs of our clients through a total of nine platforms that accelerate development timelines while minimizing risk." Since launching its proprietary cell line platform 'S-CHOice®' in 2020, Samsung Biologics has introduced a total of nine platforms, including the high-concentration biologics development support platform 'S-Tensify™' released in 2024, and the high-concentration formulation development platform 'S-HiCon™'. These platforms support clients at critical points in the drug development journey, from late discovery to production processes such as cultivation and purification, as well as formulation development.

Lee Taehee added, "Once we establish our own master cell bank (MCB) within this year, we expect to further shorten development timelines. Based on our accumulated track record, we will help clients effectively overcome the challenges they may face during new drug development with tailored strategies."

Samsung Biologics' CDO business, under the brand 'Agile. Flexible. Focused on You,' has achieved steady results, securing a total of 146 contracts as of the first half of this year. In addition, Samsung Biologics recently launched the 'Samsung Organoids' service and unveiled a CRDMO (Contract Research, Development, and Manufacturing Organization) strategy, expanding its business scope beyond CDO and CMO to include CRO (Contract Research Organization) services at the early discovery stage. The goal is to achieve an 'early lock-in' effect by starting collaboration with clients from the initial stages of drug development.

Meanwhile, at this year's BIX, Samsung Biologics set up a solo booth for the second consecutive year, actively promoting its end-to-end service capabilities that can meet all client needs. The company highlighted its goal to secure a global-leading production capacity of 1,324,000 liters by 2032, as well as its service capabilities in various modalities such as antibody-drug conjugates (ADC) and adeno-associated virus (AAV). This year's BIX event is being held at COEX in Gangnam-gu, Seoul, from October 15 to 17, with participation expected from about 300 companies and more than 12,000 visitors.

This content was produced with the assistance of AI translation services.